We are live on ! Find out more
ABBV icon

AbbVie
ABBV

249.57 USD
+5.46
2.24%
At close Updated Jul 16, 10:10 AM EDT
1 day
2.24%
5 days
-0.57%
1 month
12.18%
3 months
19.42%
6 months
16.43%
Year to date
8.84%
1 year
30.95%
5 years
112.4%
10 years
292.65%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 57,000

Healthcare Drug Manufacturers - General
0
Funds holding %
of 8,123 funds
Explore Fund Trends
0
Positive news %
of 81 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™